Fragile X Syndrome: Clinical Trials

115 trials for Fragile X Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

67 completed, 14 recruiting, 10 unknown, 7 terminated. 49 Phase 2, 21 Not applicable, 16 Phase 1, 13 Phase 3, 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 249Completed 32, Not yet recruiting 4, Recruiting 4, Terminated 3, Active not recruiting 2, Suspended 2, Unknown 1, Withdrawn 1
Not applicable21Completed 9, Recruiting 6, Unknown 3, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1
Phase 116Completed 12, Enrolling by invitation 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 313Completed 8, Active not recruiting 2, Terminated 2, Not yet recruiting 1
Phase 44Completed 3, Recruiting 1
Early Phase 11Completed 1

Follow Fragile X Syndrome: new trials by email Literature Review of Fragile X Syndrome trials Research Report on Fragile X Syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome
S247240 Low dose, S247240 Middle dose, S247240 High dose - Fragile X Syndrome (FXS)
Phase 2Not yet recruitingInstitut de Recherches Internationales Servier (I.R.I.S.)1002027-01-252026-11-12
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
Phase 2 / Phase 3Not yet recruitingSpinogenix1202026-12-012026-10-09
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
SRX246, Placebo - Aggressive Behavior in Fragile X Syndome
Phase 2Not yet recruitingAzevan Pharmaceuticals802026-12-012026-10-30
Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance
EMPOWER-ND - Neurodevelopmental Disorders, Autism Spectrum Disorder (ASD)
Not applicableNot yet recruitingBoston University Charles River Campus502026-11-012026-10-27
The Neurocognitive Bases of Trust in Intellectual Disability
Confidence adjustment assessment, clinical assessment, Cognitive assessment - Down Syndrome (Trisomy 21), Fragile X Syndrome (FXS)
RecruitingHospices Civils de Lyon1122026-07-172026-08-05
Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome
CTH120, CTH120 placebo hard capsules - Fragile X Syndrome (FXS), Fragile X Syndrome
Phase 2RecruitingConnecta Therapeutics, S.L.302026-05-212026-07-17
Optical Imaging in X-linked Disorders.
Clinical assessment, Parental questionnaires, Cognitive assessment - Fragile X Syndrome (FXS), Creatine Transporter Deficiency
Not applicableRecruitingHospices Civils de Lyon1182026-03-302026-05-15
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD)
RecruitingHealing Hope International1002026-03-012026-03-25
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379 - Fragile X Syndrome
Phase 2RecruitingMirum Pharmaceuticals, Inc.602025-11-222026-09-29
Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X Syndrome
CBD Oral Solution, Placebo - Fragile X Syndrome
Phase 2RecruitingUniversité de Sherbrooke402025-09-012026-08-28
Effect of CBD on the Brain
CBD Oral Solution (eCBD system Target), Placebo - Fragile X Syndrome
Phase 2Not yet recruitingUniversité de Sherbrooke502025-05-012025-02-17
Physical Activity and Community EmPOWERment Project
PACE Program - Intellectual Disability, Neurodevelopmental Disorders
Not applicableRecruitingUniversity of North Carolina, Chapel Hill3762025-01-102026-02-23
Neural Biomarkers in Fragile X Syndrome
Any - Fragile X Syndrome (FXS), Neurotypical Adults
CompletedConnecta Therapeutics, S.L.202024-12-162025-05-04
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Blood sample - Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
RecruitingAssistance Publique - Hôpitaux de Paris5502024-10-232026-10-21
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Sertraline, Placebo - Neurodevelopmental Disorders, Autism
Phase 2RecruitingHolland Bloorview Kids Rehabilitation Hospital1302024-09-162026-07-27
Study of SPG601 in Adult Men With Fragile X Syndrome
SPG601, Placebo - Fragile X Syndrome
Phase 2CompletedSpinogenix102024-07-052026-05-26
Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)
Gaboxadol, Placebo - Fragile X Syndrome
Phase 2CompletedCraig Erickson102024-01-292026-09-30
Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X Syndrome
Probiotics - Fragile X Syndrome
Not applicableUnknownSpecila hospital for cerebral palsy and developmental neurology152024-01-012024-06-03
Speech-in-noise Perception in Autism and Fragile X
Mismatch negativity - Autism Spectrum Disorder, Fragile X Syndrome
Not applicableCompletedChildren's Hospital Medical Center, Cincinnati432023-11-102026-11-04
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
Functional Behavioral Training (FBT), Positive Parenting Strategies-Treatment as Usual - Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis
Not applicableActive not recruitingRush University Medical Center792023-09-152026-09-18

Showing 20 of 115. Sign in to see all of them.

Narrower conditions

Autism Spectrum Disorder (17)  ·  Intellectual Disability (16)  ·  Autistic Disorder (12)  ·  Down Syndrome (9)  ·  Genetic Diseases, Inborn (8)  ·  Neurodevelopmental Disorders (8)  ·  Neurobehavioral Manifestations (7)  ·  Congenital Abnormalities (6)  ·  Genetic Diseases, X-Linked (6)  ·  Angelman Syndrome (5)  ·  Developmental Disabilities (5)  ·  Prader-Willi Syndrome (5)  ·  Williams Syndrome (5)  ·  Anxiety Disorders (4)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (115)  ·  Heredodegenerative Disorders, Nervous System (115)  ·  Neurologic Manifestations (115)  ·  Sex Chromosome Disorders (113)  ·  Chromosome Disorders (112)  ·  Nervous System Diseases (112)  ·  X-Linked Intellectual Disability (111)  ·  Congenital Abnormalities (109)  ·  Genetic Diseases, X-Linked (109)  ·  Neurobehavioral Manifestations (108)  ·  Genetic Diseases, Inborn (107)  ·  Intellectual Disability (99)  ·  Mental Disorders (43)  ·  Neurodevelopmental Disorders (29)  ·  Pathological Conditions, Signs and Symptoms (24)

Interventions

mavoglurant (6)  ·  Metformin (5)  ·  arbaclofen placarbil (5)  ·  BPN14770 (4)  ·  Minocycline (4)  ·  gaboxadol (4)  ·  2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine (3)  ·  Acamprosate (3)  ·  Lovastatin (3)  ·  Ascorbic Acid (2)  ·  Baclofen (2)  ·  Donepezil (2)  ·  Mental Status and Dementia Tests (2)  ·  Methylphenidate (2)  ·  Sertraline (2)

Sponsors

Seaside Therapeutics, Inc. (9)  ·  Children's Hospital Medical Center, Cincinnati (8)  ·  Stanford University (7)  ·  Novartis Pharmaceuticals (6)  ·  University of California, Davis (6)  ·  Tetra Discovery Partners (4)  ·  Université de Sherbrooke (4)  ·  Connecta Therapeutics, S.L. (3)  ·  Hoffmann-La Roche (3)  ·  Indiana University (3)  ·  RTI International (3)  ·  Bambino Gesù Hospital and Research Institute (2)  ·  Elizabeth Berry-Kravis (2)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2)  ·  Hospices Civils de Lyon (2)

Countries

United States (82)  ·  Spain (14)  ·  France (13)  ·  Canada (12)  ·  Australia (8)  ·  Italy (8)  ·  United Kingdom (8)  ·  Germany (5)  ·  Switzerland (5)  ·  Denmark (4)  ·  Israel (4)  ·  Belgium (3)  ·  New Zealand (3)  ·  Sweden (3)  ·  Netherlands (2)

Top investigators

Elizabeth Berry-Kravis, MD, PhD (5)  ·  Randi J Hagerman, MD (4)  ·  Allan L Reiss (3)  ·  Bryan King, MD, PhD (3)  ·  Craig Erickson, MD (3)  ·  Craig Erikson, MD (3)  ·  Elizabeth Berry-Kravis, MD (3)  ·  James McCracken, MD (3)  ·  Jeremy Veenstra-VanderWeele, MD (3)  ·  Lawrence Ginsberg, MD (3)  ·  Linmarie Sikich, MD (3)  ·  Paul Wang, M.D. (3)  ·  Randi Hagerman, MD (3)

Results publications

PMID 26764156, PMID 26855682, PMID 33395098, PMID 35794169, PMID 20937127, PMID 21059347, PMID 21209411, PMID 21862226, PMID 24285681, PMID 24354947, PMID 25187257, PMID 27612457, PMID 28764646, PMID 29875084, PMID 30153790, PMID 30455171, PMID 30982467, PMID 31315600, PMID 31549310, PMID 32316911, PMID 32555262, PMID 32660869, PMID 33218305, PMID 33473111, PMID 33927413, PMID 34690787, PMID 35053752, PMID 35142618, PMID 36167501, PMID 36180840, PMID 36434514, PMID 37850681, PMID 39248107, PMID 39332280, PMID 39483619, PMID 41254489, PMID 41291951, PMID 42104256

NIH funding

2009 (2), K23HD109375 (2), 2025 (1), K23MH077554 (1), R01AG076678 (1), R01HD071987 (1), R01HD076189 (1), R01HD108222 (1), R34MH085899 (1), U01NS096767 (1), U54HD082008 (1), U54HD104461 (1)